The antileprosy agent B.663 (Clofazimine) and the reticuloendothelial system.
D000814:Aniline Compounds / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000890:Anti-Infective Agents / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D003864:Depression, Chemical; D004893:Erythema Nodosum / Q000517:prevention & control; D008099:Liver / Q000166:cytology / Q000187:drug effects; D008168:Lung / Q000166:cytology; D008198:Lymph Nodes / Q000166:cytology / Q000187:drug effects; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D008854:Microscopy, Electron; D008858:Microscopy, Phase-Contrast; D012157:Mononuclear Phagocyte System / Q000378:metabolism*; D010587:Phagocytosis / Q000187:drug effects; D010619:Phenazines / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use
D000814:Aniline Compounds; D000890:Anti-Infective Agents; D010619:Phenazines